sorry, we can't preview this file

crc-22-0161-s04.pptx (42.51 kB)

Supplemental Table S4 from Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer

figure

posted on 2023-04-04, 01:46 authored by Ryon P. Graf, Virginia Fisher, James Creeden, Alexa B. Schrock, Jeffrey S. Ross, Halla Nimeiri, Geoffrey R. Oxnard, Samuel J. Klempner

Summary of TMB ranges per cohort and MSI. The median and interquartile range of TMB is shown per group within the cohorts, grouped by MSI status.

Funding

AGA Research Foundation (American Gastroenterological Association (AGA) Research Foundation)

History

ARTICLE ABSTRACT

Using real-world data, we sought to evaluate robustness of these clinical associations using the same assay platform and biomarker cut-off point used in both clinical trials and pan-tumor CDx approvals for later treatment lines. TMB ≥ 10 robustly identified patients with mEG with more favorable outcomes on ICPI monotherapy versus chemotherapy and suggests this subset of patients could be targeted for further trial development.